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Essentials
• Recently, ADAMTS-13 has been shown to undergo
substrate induced conformation activation.
• Conformational quiescence of ADAMTS-13 may serve
to prevent off-target proteolysis in plasma.
• Conformationally active ADAMTS-13 variants are cap-
able of proteolysing the Aa chain of fibrinogen.
• This should be considered as ADAMTS-13 variants are
developed as potential therapeutic agents.
Click to hear Dr Zheng’s presentation on structure function
and cofactor-dependent regulation of ADAMTS-13
Summary. Background: Recent work has revealed that
ADAMTS-13 circulates in a ‘closed’ conformation, only
fully interacting with von Willebrand factor (VWF) fol-
lowing a conformational change. We hypothesized that
this conformational quiescence also maintains the sub-
strate specificity of ADAMTS-13 and that the ‘open’ con-
formation of the protease might facilitate proteolytic
promiscuity. Objectives: To identify a novel substrate for
a constitutively active gain of function (GoF) ADAMTS-
13 variant (R568K/F592Y/R660K/Y661F/Y665F). Meth-
ods: Fibrinogen proteolysis was characterized using SDS
PAGE and liquid chromatography-tandem mass spectro-
metry (LC-MS/MS). Fibrin formation was monitored by
turbidity measurements and fibrin structure visualized by
confocal microscopy. Results: ADAMTS-13 exhibits pro-
teolytic activity against the Aa chain of human
fibrinogen, but this is only manifest on its conformational
activation. Accordingly, the GoF ADAMTS-13 variant
and truncated variants such as MDTCS exhibit this activ-
ity. The cleavage site has been determined by LC-MS/MS
to be Aa chain Lys225-Met226. Proteolysis of fibrinogen
by GoF ADAMTS-13 impairs fibrin formation in
plasma-based assays, alters clot structure and increases
clot permeability. Although GoF ADAMTS-13 does not
appear to proteolyse preformed cross-linked fibrin, its
proteolytic activity against fibrinogen increases the sus-
ceptibility of fibrin to tissue-type plasminogen activator
(t-PA)-induced lysis by plasmin and increases the fibrin
clearance rate more than 8-fold compared with wild-type
(WT) ADAMTS-13 (EC50 values of 3.0  1.7 nM
and 25.2  9.7 nM, respectively) in in vitro thrombo-
sis models. Conclusion: The ‘closed’ conformation of
ADAMTS-13 restricts its specificity and protects against
fibrinogenolysis. Induced substrate promiscuity will be
important as ADAMTS-13 variants are developed as
potential therapeutic agents against thrombotic thrombo-
cytopenic purpura (TTP) and other cardiovascular
diseases.
Keywords: ADAMTS-13 protein, human; allosteric
regulation; fibrinogen; fibrinolysis; protein conformation;
von Willebrand factor.
Introduction
ADAMTS-13 is a multi-domain glycoprotein that prote-
olyses the A2 domain of von Willebrand factor (VWF)
and regulates its hemostatic function [1–4]. Multiple
VWF-binding exosites have been identified across a num-
ber of ADAMTS-13 domains [5], which have informed
the development of a so-called ‘molecular zipper’ model
of interaction and proteolysis [6–16]. An interaction
occurs between ADAMTS-13 and globular VWF, in
which the distal C-terminal tail of ADAMTS-13 and the
C-terminal D4-CK domains of VWF make contact [17].
This moderate affinity binding (KD of ~80–120 nM) inter-
action has been described as a positioning one, allowing
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a small proportion of ADAMTS-13 to circulate in com-
plex with VWF [5,18]. Much tighter binding occurs fol-
lowing A2 domain unfolding, between the ADAMTS-13
spacer domain exosites (Arg659, Arg660, Tyr661 and
Tyr665) and the newly exposed VWF A2 residues
Asn1651-Arg1668 [13]. Next, exosites in the cysteine-rich
domain (Gly471-Val474) and the disintegrin-like domain
(Arg349 and Leu350) of ADAMTS-13 interact with com-
plementary binding sites in the A2 domain, progressively
closer to the cleavage site [9,12]. This facilitates position-
ing of the ADAMTS-13 metalloprotease domain over the
VWF scissile bond, with the ADAMTS-13 S3 subsite
(Leu198, Leu232 and Leu274) binding to the VWF P3
residue Leu1603 [10]. The ADAMTS-13 active site con-
tains a 3xHis Zn2+ binding motif and catalytic Glu resi-
due that are flanked by S1 and S1’ pockets, which
specifically bind the P1 (Tyr1605) and P1’ (Met 1606)
residues of the VWF scissile bond, leading to proteolysis
[15].
There are three properties of ADAMTS-13 that are
unusual. Firstly, it is secreted and circulates as an
active enzyme [19,20]. Secondly, ADAMTS-13 has a
long plasma half-life (2–3 days) and has no known
physiological inhibitors [21]. Thirdly, ADAMTS-13
appears to display no off-target proteolysis, acting only
on VWF. The first of these properties has, until
recently, been explained by the dependence of
ADAMTS-13 proteolytic function on VWF conforma-
tion and the exposure of its complementary binding
sites. However, it has recently been shown that
ADAMTS-13 undergoes its own conformational change
in order to attain a fully active state [22,23]. In this
new model of ADAMTS-13 function the enzyme circu-
lates in a ‘closed’ conformation mediated by binding
between its spacer and CUB domains [22]. Upon bind-
ing to the D4-CK domains of globular VWF,
ADAMTS-13 is induced to adopt an ‘open’ conforma-
tion exposing the cryptic spacer domain exosites (this
conformational change also exposes the autoantibody
epitopes recognized in thrombotic thrombocytopenic
purpura) [22]. Some ADAMTS-13 variants, such as the
gain of function (GoF) spacer domain variant first
described by Jian et al. [24], are in a pre-activated
‘open’ conformation [22].
The finding that ADAMTS-13 circulates in a ‘closed’
conformation explains how it can be secreted as an active
enzyme, with its proteolytic potential only being achieved
upon binding to its substrate. This may also explain the
substrate specificity of ADAMTS-13, because in a ‘closed’
conformation the active site of the enzyme may not be
accessible to additional substrates. However, when
ADAMTS-13 adopts its ‘open’ conformation it may be
able to proteolyse other proteins at the site of vascular
injury. In this report, we demonstrate that conformational
activation of ADAMTS-13 reveals its ability to proteolyt-
ically cleave fibrinogen.
Methods
Fibrinogen proteolysis examined by SDS PAGE and Western
blot
ADAMTS-13 variants were expressed in HEK293S stable
cell lines as previously described (15) and purified by
immunoaffinity using a-c-myc agarose (Thermo Fisher,
Waltham, MA, USA). Fibrinogen, purified from human
plasma, was purchased from Sigma-Aldrich (St. Louis,
MO, USA). ADAMTS-13 was pre-incubated at 37 °C for
1 h in the presence of 5 mM CaCl2 prior to the addition of
fibrinogen to a final concentration of 1 mg mL1. Reac-
tions were incubated at 37 °C and stopped after 180 min
by the addition of SDS PAGE loading buffer. Samples
were run on 4–12% BIS-TRIS gels in MOPS buffer
(Invitrogen, Carlsbad, CA, USA) and stained with
Coomassie or transferred to nitrocellulose for Western
blot using a pAb against the Aa chain (residues 21–320) of
human fibrinogen (Abcam, Cambridge, UK).
Mass spectrometry
For MALDI-TOF mass spectrometry, fibrinogen
(1 mg mL1) was digested in solution with 50 nM GoF
ADAMTS-13 overnight at 37 °C. Reduced and non-
reduced samples were applied to C18 tips (Thermo
Fisher) and eluted in 0.1% Trifluoroacetic acid in 95%
acetonitrile. Using sinapinic acid as matrix, samples were
analyzed using an Applied Biosystems (Foster City, CA,
USA) Voyager DE Pro Biospectrometry workstation and
DataExplorer processing software.
For liquid chromatography-tandem mass spectrometry
(LC-MS/MS) mass spectrometry, fibrinogen (digested in
solution as above) was run on an 8% BIS-TRIS gel with
MES (2-(N-morpholino)ethanesulfonic acid) buffer (Invit-
rogen) under reducing conditions. Proteolytic fragments
were excised from the gel and an in-gel trypsin digest was
performed as per the manufacturer’s guidelines (Promega,
Madison, WI, USA). Samples were analyzed on a Micro-
mass QToF Premier with MAssLynx 4.1 software.
Fibrin formation and fibrinolysis assays
Turbidity assays of fibrin formation and fibrinolysis
were performed as previously described [25]. Briefly,
normal human plasma, diluted 1 : 2 in HEPES buffer
containing 20 mM CaCl2, was incubated in a clear 96-
well plate for 20 min at 37 °C with and without
ADAMTS-13. Fibrin formation was initiated by the
addition of 2 nM human thrombin (Sigma-Aldrich) and
was followed by absorbance at 405 nm at 15-s intervals
for 60 min using a FLUOstar Omega (BMG Labtech,
Ortenberg, Germany) plate reader maintained at 37°C.
For SDS PAGE of fibrin cross-linking, 5 lM human
fibrinogen was pre-incubated with and without 50 nM
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ADAMTS-13 for 1 h at 37° before the addition of 2 nM
thrombin and 20 mM CaCl2. Cross-linking of fibrin in
these samples was allowed to proceed for either 20 min
or 1 h before the sample was solubilized by the addition
of 4% SDS and 2% b-mercaptoethanol.
Fibrin formed, as above, in the absence of ADAMTS-
13 was used to determine whether ADAMTS-13 is cap-
able of proteolysing cross-linked fibrin. Fibrin formation
was allowed to proceed for 30 min at 37 °C following the
addition of 2 nM thrombin, in clear 96-well plates. Wells
were then overlaid with either 1 lg mL1 tissue-type plas-
minogen activator (t-PA) (Sigma-Aldrich) or 50 nM
ADAMTS-13 and the absorbance at 405 nm was
recorded at 60-s intervals for 180 min.
To determine the effect of ADAMTS-13 proteolysis of
fibrinogen on fibrinolysis, fibrin was formed in the pres-
ence of 100 ng mL1 t-PA after pre-incubation with and
without ADAMTS-13. Fibrin formation/lysis was deter-
mined by measuring the absorbance at 405 nm at 15-s
intervals for 30 min. Lysis times were calculated from the
two points of 50% maximal absorbance.
Permeation assay
Permeation assays were performed as previously described
[26]. Fibrin formation was initiated by the addition of
2 nM thrombin to normal human plasma and pre-incu-
bated with and without 50 nM ADAMTS-13, in 10 mL
disposable columns (Biorad, Hercules, CA, USA). After
30 min at 37 °C the 200-lL fibrin bed was topped with
HEPES buffer and the volume of buffer passing through
the column was manually recorded at 10-min intervals.
Confocal microscopy
Normal human plasma, supplemented with 150 lg mL1
AlexaFluor594 labelled human fibrinogen (Invitrogen),
was pre-incubated with and without 50 nM GoF
ADAMTS-13 for 40 min at 37 °C. Fibrin formation was
performed in glass chamber slides (Ibidi GmbH, Planegg,
Germany), by the addition of 2 nM thrombin and incuba-
tion at 37 °C for 30 min. Images were acquired using a
Zeiss LSM780 (Carl Zeiss AG Oberkochen, Germany)
confocal microscope with a Plan-Apo 10x/0.45 objective
and processed using FIJI imaging software (ImageJ,
Madison, WI, USA).
In vitro thrombosis model
Vena8 Fluoro + biochips (Cellix) were coated with
200 lg mL1 collagen type III (Southern Biotech, Bir-
mingham, AL, USA) and 100 pM tissue factor (Sigma-
Aldrich) before being blocked with coagulation buffer
(1% bovine serum albumin, 75 mM CaCl2, 37.5 mM
MgCl2 in HEPES buffer). Whole human blood was col-
lected on 129 mM trisodium citrate (1 : 10 dilution).
Platelets were labelled with 10 lM DiOC6 (Sigma-Aldrich)
and 100 lg mL1 AlexaFluor594 labelled fibrinogen
(Invitrogen) was added to visualize fibrin formation.
Citrated blood was diluted 9 : 1 with coagulation buffer
immediately before perfusion over the collagen surface at
1500 s1 for 3 min. This was repeated three times to pro-
vide uninterrupted flow of coagulating blood for sufficient
time to allow the formation of stable fibrin clots.
This was followed by a further 5-min perfusion with
blood, collected on D-Phenylalanyl-prolyl-arginyl Chloro-
methyl Ketone (PPACK) (Sigma-Aldrich) and enoxaparin
(low-molecular-weight heparin from Sanofi-aventis,
Bridgewater, NJ, USA), and supplemented with DiOC6
labelled platelets, labelled fibrinogen and increasing con-
centrations of ADAMTS-13. At the end of this period
the fluorescence intensity of DiOC6 platelets and
AlexaFluor594 fibrin was measured at multiple locations
along the biochip channel and used to determine the
EC50 of ADAMTS-13 cleavage of fibrin clots.
Results
Conformationally active ADAMTS-13 (caADAMTS-13)
proteolyses the Aa chain of fibrinogen
On SDS PAGE, under non-reducing conditions, fibrino-
gen migrated as a single, broad band at approximately
340 kDa (Fig. 1C and D). When reduced, the Aa, Bb
and c chains of fibrinogen were resolved at 65, 56 and
47 kDa, respectively (Fig. 1A and B). When fibrinogen
was pre-incubated with wild-type (WT) ADAMTS-13, or
an inactive active site variant (E225A ADAMTS-13),
there was no observable alteration of these migration
patterns. However, when pre-incubated with the GoF
ADAMTS-13 variant (Fig. 1A–D), WT ADAMTS-13
that had been pre-incubated with the VWF D4CK
domain fragment (Fig. 1E) or the C-terminal truncated
(ca) variants, WT and GoF MDTCS (Fig. 1F), proteoly-
sis of fibrinogen was observed. This resulted in a
depletion of intact 340 kDa fibrinogen, observed under
non-reducing conditions, and depletion of the intact Aa
chain observed under reducing conditions. Proteolysis of
the Aa chain released a 40 kDa fragment from fibrino-
gen, reducing its size to 290 kDa and then 250 kDa.
Under reducing conditions, both this 40 kDa fragment
and the remaining 25 kDa Aa chain fragment were
detected. All of these proteolytic fragments were detected
on Western blot using a pAb raised against the Aa
chain. Proteolysis was abolished in the presence of an
inhibitory mAb (imAb, 3H9), directed against the
ADAMTS-13 metalloprotease domain (Fig. 1A) but was
not inhibited by the serine protease inhibitor PPACK
(Fig. 1E).
Further analysis of the fibrinogen Aa proteolytic frag-
ments was performed using LC-MS/MS. Both fragments
(40 kDa and 25 kDa), resulting from an in-solution
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digestion with GoF ADAMTS-13, were resolved by SDS
PAGE (Fig. 2A). These bands were excised and subjected
to an in-gel digestion with trypsin. The resulting peptides
were sequenced by LC-MS/MS (Tables S1 and S2) and
mapped onto the fibrinogen Aa amino acid sequence
(Fig. 2B). Coverage of the fibrinogen Aa sequence in the
25 kDa fragment was limited to the N-terminal residues
up to, and including, Lys225. Peptides identified in the
40 kDa fragment were mapped exclusively to the C-term-
inal portion of the sequence, beginning at Met226. This
indicated that the site of ADAMTS-13 proteolysis was
the Lys225-Met226 peptide bond (Fig. 2C), which is posi-
tioned in the protease-sensitive hinge region of the Aa
chain (Fig. 2D). The lysine residue in the P1 position is
unusual, but when the ADAMTS-13 proteolysis site in
the short VWF A2 domain fragment VWF115 (Tyr1605-
Met1606) was mutated to represent the site of proteolysis
in fibrinogen (Tyr1605Lys VWF115), proteolysis still
occurred (Fig. S1).
caADAMTS-13 proteolysis of fibrinogen alters fibrin
formation and clot structure
The formation of fibrin in plasma, or in a purified com-
ponent assay, following the addition of thrombin can be
determined by an increase in absorbance at 405 nm [25].
Neither the extent of this absorbance change or the rate
at which it occurs was altered when plasma was pre-
incubated for 20 min with WT ADAMTS-13 or the inac-
tive active site variant E225A ADAMTS-13 (Fig. 3A).
However, pre-incubation with GoF ADAMTS-13 resulted
in a decrease in the maximal absorbance. The extent of
this decreased absorbance was dose dependent (Fig. 3B),
was proportional to the duration of pre-incubation with
GoF ADAMTS-13 (Fig. 3A) and was abolished in the
presence of an inhibitory mAb against ADAMTS-13
(Fig. 3A).
The decrease in absorbance in the presence of WT
ADAMTS-13 (Fig. 3B), even at high concentrations, was
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Fig. 1. ADAMTS-13 proteolysis of fibrinogen determined by SDS PAGE and Western blot. Purified human fibrinogen was incubated at 37 °C
with 50 nM purified ADAMTS-13 or MDTCS. Samples taken after 180 min were run on SDS PAGE under reducing (A, B, E and F) and
non-reducing conditions (C and D) and analyzed by Coomassie staining (A and C) and by Western blot using a pAb against the Aa chain of
fibrinogen (B, D, E and F). Intact fibrinogen (C and D) and the Aa chain (A, B, E and F) are indicated by white arrows. Proteolytic fragments
are indicated by black arrows. Fibrinogen proteolysis by wild-type (WT) ADAMTS-13 is only observed after a pre-incubation with the VWF
D4CK domain fragment (E). Proteolysis is completely inhibited when ADAMTS-13 is pre-incubated with an inhibitory mAb (imAb) targeted
against the metalloprotease domain (3H9) (A). Proteolysis of fibrinogen is not inhibited by the serine protease inhibitor D-Phenylalanyl-prolyl-
arginyl Chloromethyl Ketone (PPACK) (E).
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insignificant (P > 0.06). However, in the presence of
50 nM GoF ADAMTS-13, there was a progressive and
significant (P < 0.01) decrease in absorbance. This
demonstrates that the proteolysis of fibrinogen in plasma,
and the resulting alteration of fibrin formation, were
dependent on ADAMTS-13 conformation.
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Fig. 2. LC-MS/MS of fibrinogen cleavage products. (A) Purified human fibrinogen was incubated overnight at 37 °C with or without 50 nM
purified gain of function (GoF) ADAMTS-13. The proteolysis reactions were separated by SDS PAGE under reducing conditions. The two
proteolytic fragments of the Aa chain (40 and 25 kDa) were excised and subjected to an in-gel trypsin digestion. (B) The resulting peptides
were sequenced by liquid chromatography-tandem mass spectrometry (LC-MS/MS), identified against Swissprot entry P02671 (FIBA_HU-
MAN) and mapped onto the fibrinogen Aa sequence. Sequences in bold were identified in the 25 kDa fragment and those that are underlined
were identified in the 40 kDa fragment. (C) The domain structure of human fibrinogen is determined by interchain disulphide bonds between
the Aa, Bb and c chains (solid black lines). Thrombin cleavage occurs at the N-terminus of the Aa and Bb chains (black dashed lines) liberat-
ing fibrinopeptide A (FpA) and fibrinopeptide B (FpB). ADAMTS-13 proteolysis results in a 40 kDa C-terminal cleavage fragment of the Aa
chain (bold dashed lines) as determined by SDS PAGE (Fig. 1) and MALDI TOF mass spectrometry. Using LC-MS/MS analysis of the cleav-
age fragments (supplementary Tables S1 and S2) the site of proteolysis has been determined to be between Lys225 and Met226. Therefore the
released cleavage fragment contains aIIbb3, FXIIIa and a2-antiplasmin binding sites. (D) The Lys225-Met226 bond is situated in the protease
sensitive hinge region of the Aa chain, which is only partially resolved in this crystal structure of human fibrinogen (3GHG) [28]. The unre-
solved flexible a-C domain, represented here in blue, is completely removed by GoF ADAMTS-13 proteolysis.
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Stabilization of fibrin monomers, firstly through c-c
dimer formation and later through a chain cross-linking,
can be visualized by SDS PAGE [27]. Upon proteolysis of
fibrinogen by thrombin there was a shift in the migration
of the Aa and Bb chains corresponding to the release of
the fibrinopeptides FpA and FpB (Fig. 3C). Following
activation of factor (F) XIII by thrombin, both c-c dimers
and lower order a-polymers were formed within 20 min
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Fig. 3. ADAMTS-13 proteolysis of fibrinogen alters fibrin formation. (A) The formation of fibrin in normal human plasma, with and without
pre-incubation with 50 nM ADAMTS-13, was initiated by the addition of 2 nM thrombin and determined by increased absorbance at 405 nm
(representative of n = 5). Unless indicated, the duration of the pre-incubation was 20 min. (B) Fibrin formation assays were performed in the
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Polymerization of purified fibrinogen (with and without pre-incubation with ADAMTS-13) was initiated by the addition of 2 nM thrombin and
allowed to proceed for either 0, 20 or 60 min before sample solubilization. To examine the extent of fibrin cross-linking, samples were run on
SDS PAGE for either Coomassie staining (C) or Western blot using a pAb against the fibrin(ogen) a chain (D).
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(Fig. 3C). Within 1 h, higher order a-polymers were
formed. This was also the case for fibrinogen that had
been pre-incubated with WT ADAMTS-13 before the
addition of thrombin (Fig. 3C). However, proteolysis of
the Aa chain of fibrinogen during pre-incubation with
GoF ADAMTS-13, indicated by the appearance of
N-terminal and C-terminal Aa chain fragments, resulted
in reduced a-polymer formation (Fig. 3C and D).
The reduced absorbance change in fibrin formation
assays, and reduced a-polymer formation indicated by
SDS PAGE, suggested that proteolysis of fibrinogen by
caADAMTS-13 would alter the density of the fibrin net-
work in clotting plasma. This was confirmed by confocal
microscopy of the fibrin network formed in the absence
(Fig. 4A) and presence (Fig. 4B) of GoF ADAMTS-13.
In ADAMTS-13-treated samples, fibrin appeared to be
less dense, with reduced lateral association resulting in
larger pores. This was also reflected in the increased per-
meability of these clots (Fig. 4C).
caADAMTS-13 proteolysis of fibrinogen increases the
susceptibility of fibrin to plasmin cleavage
Once fully cross-linked, 30 min after thrombin addition,
fibrin appeared to be resistant to proteolysis by
caADAMTS-13 (Fig. 5A). Accordingly, fibrin formed fol-
lowing pre-incubation with GoF ADAMTS-13, despite
being less dense, did not appear to be proteolysed within
the course of fibrin formation assays (Fig. 3A). However,
when fibrin was formed in the presence of ADAMTS-13
and t-PA the lysis time was reduced (Fig. 5B) to
14.5  1.2 min (P < 0.05) and 12.8  0.2 min (P < 0.001)
for WT and GoF ADAMTS-13, respectively, compared
with 16.9  0.4 min for t-PA alone (Fig. 5C).
caADAMTS-13 proteolysis of fibrinogen increases the rate of
clearance of fibrin thrombi in vitro
The consequence of fibrinogen proteolysis by caA-
DAMTS-13 for the formation of a stable thrombus has
been examined using an in vitro perfusion model. In the
absence of ADAMTS-13, the large fibrin and platelet-rich
thrombi, formed during an initial 9-min perfusion period,
remained stable throughout the second perfusion period
(Fig. 6A). When ADAMTS-13 was present during the
second period of perfusion, there was a dose-dependent
reduction in the residual platelet fluorescence (Fig. 6A
and B). The EC50 values of WT ADAMTS-13 and GoF
ADAMTS-13 in this assay, in terms of platelet clearance,
were 11.2  2.8 nM and 1.5  0.9 nM, respectively.
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WT ADAMTS-13 had little effect on the fibrin compo-
nent of these thrombi; the reduction in fibrin fluorescence
was not significant (P > 0.2) even at concentrations above
10 nM (Fig. 6C). GoF ADAMTS-13, on the other hand,
induced significant reduction of fibrin fluorescence
(P < 0.05) at all concentrations above 2.5 nM. The EC50
values of WT ADAMTS-13 and GoF ADAMTS-13 in
this assay, in terms of fibrin clearance, were
25.2  9.7 nM and 3.0  1.7 nM, respectively.
Discussion
ADAMTS-13 proteolysis of fibrinogen is conformation
dependent
ADAMTS-13 is capable of proteolysing the Aa chain of
human fibrinogen between Lys225 and Met226, a site sug-
gested by the partial crystal structure of human fibrinogen
[28] to be surface exposed and accessible (Fig. 2D). This
cleavage site bears some resemblance to the scissile bond
at Tyr1605-Met1606 of VWF, which is proteolysed by
ADAMTS-13. Both have methionine in the P1’ position,
leucine in the P3 position and small, hydrophobic residues
in the P2 position (valine in VWF and isoleucine in
fibrinogen). When Tyr1605 in a short VWF substrate
(VWF115) is mutated to lysine, proteolysis by ADAMTS-
13 still occurs (Fig. S1). This concurs with previous stud-
ies of substrate specificity of ADAMTS-13, in which the
substitution of Tyr1605 to lysine did not abolish the
proteolysis of a VWF73 expressing phage [29,30]. Our
findings suggest proteolysis of fibrinogen by GoF
ADAMTS-13 will be less efficient than its cleavage of
unfolded VWF. Proteolysis of Tyr1605Lys VWF115 by
GoF ADAMTS-13 is incomplete within 120 min, com-
pared with the complete proteolysis within 60 min
observed in WT VWF115 cleavage assays (Fig. S1).
Importantly, we have identified proteolytic activity
against fibrinogen using the GoF ADAMTS-13 variant
(Fig. 1A–D), in which the autoinhibitory spacer-CUB
domain interaction is abolished, and the truncated MDTCS
variants (Fig. 1F), which lack the C-terminal domains [22].
Therefore, it appears that only ADAMTS-13 variants that
are in a pre-activated conformation are capable of fibrino-
gen proteolysis. WT ADAMTS-13, even at high concentra-
tions (200 nM), does not exhibit proteolytic activity against
fibrinogen (Fig. S5). However, upon activation by the VWF
D4CK domain fragment, WT ADAMTS-13 attains prote-
olytic activity against fibrinogen (Fig. 1E). This strongly
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suggests that WT ADAMTS-13 in its closed conformation
would not proteolyse fibrinogen in circulation, despite the
high concentration of this potential substrate. Under flow,
in in vitro models of thrombus formation, WT ADAMTS-
13 does not appear to significantly affect the stability of
deposited fibrin (Fig. 6). Conformational activation of
ADAMTS-13 therefore serves as a mechanism to protect
fibrinogen (and possibly other plasma proteins) from off-
target proteolysis by ADAMTS-13.
It is possible that once conformationally activated, by
VWF recruited at sites of vascular injury, ADAMTS-13
may potentially engage and proteolyse fibrinogen. How-
ever, this may be unlikely. In the experiments described
in Figs 1–5, ADAMTS-13 was used at 50 nM (unless
otherwise stated) and is therefore appreciably higher than
the normal plasma concentration of ADAMTS-13, 4.1 to
7.9 nM [31]. We suggest that proteolysis of fibrinogen by
ADAMTS-13 may only be physiologically relevant, in the
context of a possible high local concentration of
ADAMTS-13 at sites of vascular injury, where VWF
induces conformation activation.
caADAMTS-13 proteolysis inhibits cross-linking of fibrin and
alters clot structure
The functional consequence of fibrinogen proteolysis by
GoF ADAMTS-13 is clear when examining fibrin forma-
tion. Proteolysis of the N-terminus of fibrinogen by
thrombin appears to be unaffected by proteolysis of the
Aa chain C-terminus by GoF ADAMTS-13 (Fig. 3C).
Fibrin formed from fibrinogen following caADAMTS-13
proteolysis, appears to form normal c-c dimers
(Fig. 3C), although there remains some residual non-
cross-linked c chain indicating that the rate of c-c dimer
formation may be marginally reduced compared with
control fibrin. This may be the result of the removal of
the FXIIIa binding site from the fibrinogen Aa chain
residues 371–425 [32] by caADAMTS-13 proteolysis
(Fig. 2C), as this interaction has been shown to play an
important regulatory role in the FXIIIa B-subunit disso-
ciation [33].
More importantly, caADAMTS-13 proteolysis of fib-
rinogen directly reduces cross-linking of the a chains of
fibrin (Fig. 3C and D). Following a 60-min pre-incuba-
tion of fibrinogen with GoF ADAMTS-13, minimal low-
order a-polymers are formed within 20 min of thrombin
addition, compared with control samples. This residual
polymer formation probably arises from the small pro-
portion of fibrinogen left intact following the incubation
with ADAMTS-13. Proteolysis of fibrinogen by GoF
ADAMTS-13 removes the a-chain residues 241–476 and
518–584 (Fig. 2C), which are required for a-chain associa-
tion [34].
As a result of reduced a chain cross-linking, fibrin for-
mation is altered in plasma treated with GoF
ADAMTS-13 (Fig. 3A and Fig. 4B). The fibrin formed
in these assays still polymerizes, through c-c dimeriza-
tion; however, the lack of a-polymer formation results in
decreased maximal absorbance, which is indicative of a
lower density fibrin network. Visualization of the fibrin
network by confocal microscopy confirms a pronounced
decrease in the density of the fibrin network in GoF
ADAMTS-13-treated plasma (Fig. 4B). Fibres in these
samples appear to be longer and less densely packed
compared with normal plasma (Fig. 4A). Even under
visual inspection, clots formed in GoF ADAMTS-13-
treated plasma appear less opaque and less viscous.
There is an apparent increase in pore size, which may
account for the significant increase in the permeability of
these clots (Fig. 4C).
caADAMTS-13 proteolysis of fibrinogen increases t-PA-
induced lysis of fibrin
The altered formation of fibrin that results from GoF
ADAMTS-13 proteolysis of fibrinogen (Fig. 3) appears to
render fibrin more susceptible to the action of t-PA/plas-
minogen (Fig. 5), significantly reducing the lysis time by
almost 25%. By removing the potential for a-chain cross-
linking, and by decreasing the density of the fibrin net-
work, ADAMTS-13 proteolysis may allow easier access
for plasmin to the coiled coil regions [35]. This may
be compounded by the loss of the a2-antiplasmin cross-
linking site at Lys303 [36] of the fibrinogen Aa chain,
following proteolysis (Fig. 2C).
Unexpectedly, given that WT ADAMTS-13 exhibits no
detectable proteolytic activity against fibrinogen, fibrin
also appears to be more susceptible to plasmin in samples
treated with WT ADAMTS-13 (Fig. 5). There is evidence
to suggest that WT ADAMTS-13 is able to bind to fib-
rinogen with moderate affinity, which is enhanced in con-
formationally active variants (Fig. S3). Therefore, even in
the absence of proteolytic activity, binding of ADAMTS-
13 may hinder plasmin cleavage of fibrin.
caADAMTS-13 proteolysis of fibrinogen enhances platelet
and fibrin clearance in in vitro models of thrombosis
In in vitro models of thrombosis WT ADAMTS-13 is
known to reduce VWF-mediated platelet recruitment to a
prothrombotic surface [37]. It also prevents further
recruitment of platelets to preformed fibrin/platelet-rich
thrombi (Fig. 6B). In this assay the EC50 of the GoF
ADAMTS-13 variant, in terms of platelet clearance, is
more than seven times lower than that of WT
ADAMTS-13. The efficacy of GoF ADAMTS-13 in this
assay is higher than expected, given that the variant exhi-
bits only a 2.5-fold increase in proteolytic activity against
VWF in static assays [22] and only a ~3-fold decease in
EC50 in platelet recruitment assays (Fig. S2). The maxi-
mal effect of WT ADAMTS-13, which acts only on
VWF-mediated platelet capture, in this assay is a ~50%
© 2016 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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decrease in platelet coverage. This suggests the remaining
50% of platelets are bound to fibrinogen. The increased
clearance of platelets by GoF ADAMTS-13 may be the
result of fibrinogen proteolysis, which removes a aIIbb3
binding site on the fibrinogen Aa chain (Fig. 2C),
thereby reducing fibrinogen-mediated platelet–platelet
interactions in the developing thrombus [38]. This is sup-
ported by the fact that the GPIIbIIIa receptor antagonist
GRR144053 induces a similar decrease in platelet cover-
age (~60%) when perfused over the preformed thrombi
in this assay (Fig. S4).
Moreover, GoF ADAMTS-13 is capable of reducing
the fibrin component of these preformed thrombi
(Fig. 6C), presumably because of the decreased density
and increased permeability of the fibrin network formed
in GoF ADAMTS-13-treated plasma. WT ADAMTS-13
does not seem to exhibit any significant effect on the fib-
rin component of the thrombi in these assays (Fig. 6C),
further supporting the hypothesis that the proteolytic
activity of ADAMTS-13 against fibrinogen is dependent
on conformation.
Off-target proteolysis may be an important consideration in
the development of ADAMTS-13-based therapies
The therapeutic potential of recombinant WT ADAMTS-
13 has already been examined in murine models of
thrombosis [39,40], ischemic stroke [41] and myocardial
ischemia [42]. That GoF ADAMTS-13 exhibits prote-
olytic activity against fibrinogen, as well as enhanced
activity against VWF, because of its pre-activated confor-
mation, could alter its therapeutic potential. Many of
these in vivo models involve the use of FeCl3 or occlusive
filaments. In FeCl3-based models the thrombus develop-
ment following injury is largely VWF dependent and the
thrombi formed are poor in fibrin [43]. In the transient
ischemia models of stroke and myocardial ischemia,
infarction is largely dependent on the inflammatory
response to reperfusion injury [42]. Therefore, these mod-
els are unlikely to illustrate the full potential of GoF
ADAMTS-13 in thrombus resolution. In experimental
[44–46] and human situations of pathological clot forma-
tion we anticipate that GoF ADAMTS-13 will have
increased efficacy compared with WT ADAMTS-13
because of its dual antiplatelet and fibrinolytic functions.
As well as the treatment of stroke [41] and myocar-
dial infarction [42], the use of recombinant ADAMTS-
13 as a replacement therapy in acquired TTP [47] and
the possibility of gene therapies to overcome
ADAMTS-13 deficiency [48] are also being investigated.
Conformationally active ADAMTS-13 variants, such as
the truncated variant MDTCS used in one gene therapy
investigation [48], although having the potential for
improved efficacy, may also carry the risk of off-target
proteolysis, particularly when administered at supra-phy-
siological concentrations.
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